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Aims Atherosclerosis is the leading cause of death in Western societies and a chronic inﬂammatory
disease. However, the key mediators linking recruitment of inﬂammatory cells to atherogenesis
remain poorly deﬁned. Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear enzyme, which plays a
role in acute inﬂammatory diseases.
Methods and results In order to test the role of PARP in atherogenesis, we applied chronic pharmaco-
logical PARP inhibition or genetic PARP1 deletion in atherosclerosis-prone apolipoprotein E-deﬁcient
mice and measured plaque formation, adhesion molecules, and features of plaque vulnerability. After
12 weeks of high-cholesterol diet, plaque formation in male apolipoprotein E-deﬁcient mice was
decreased by chronic inhibition of enzymatic PARP activity or genetic deletion of PARP1 by 46 or 51%,
respectively (P, 0.05, n  9). PARP inhibition or PARP1 deletion reduced PARP activity and diminished
expression of inducible nitric oxide synthase, vascular cell adhesion molecule-1, and P- and E-selectin.
Furthermore, chronic PARP inhibition reduced plaque macrophage (CD68) and T-cell inﬁltration (CD3),
increased ﬁbrous cap thickness, and decreased necrotic core size and cell death (P , 0.05, n  6).
Conclusion Our data provide pharmacological and genetic evidence that endogenous PARP1 is required
for atherogenesis in vivo by increasing adhesion molecules with endothelial activation, enhancing
inﬂammation, and inducing features of plaque vulnerability. Thus, inhibition of PARP1 may represent
a promising therapeutic target in atherosclerosis.
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1. Introduction
Atherosclerosis is the primary cause of myocardial infarction
and stroke and thereby the leading cause of death in
Western countries. It is a chronic inﬂammatory disease
resulting from the interaction between modiﬁed lipopro-
teins, activated endothelial cells, inﬂammatory cells, and
elements of the arterial wall.1 However, the key mediators
of atherosclerosis that may represent effective therapeutic
targets remain poorly deﬁned.
Mammalian poly(ADP-ribose)polymerase 1 (PARP1) is an
abundant nuclear chromatin-associated protein. It belongs
to a large family of enzymes that catalyse the transfer of
ADP-ribose units from their substrate b-nicotinamide
adenine dinucleotide (NADþ) covalently to themselves and
other nuclear chromatin-associated proteins.2,3 Although
PARP1 protein synthesis can be regulated in response to
several stimuli, PARP1 is principally regulated via substrate
interactions through its catalytic site. PARP1 is activated
by DNA strand breaks, and thus involved in DNA damage
response pathways. In addition, PARP1 may induce cell dys-
function or necrosis by depleting cellular energy pools.3
In vivo experiments using PARP1 deletion4 or pharmaco-
logical inhibition of PARP demonstrate a role for PARP in
acute inﬂammatory processes such as myocardial infarc-
tion,5,6 diabetes-induced endothelial dysfunction in mice,7
and lipopolysaccharide-induced septic shock.8 In contrast,
much less is known about its role in chronic inﬂammatory
diseases.
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As inﬂammation is crucially involved in atherosclerosis,1
we hypothesized that PARP1 is required for the formation
of atherosclerotic plaques. Thus, we examined the effects
of chronic PARP inhibition (by treatment with PJ34) and
genetic PARP1 deletion on plaque formation in
atherosclerosis-prone apolipoprotein E knockout
(ApoE2/2) mice.9 We found that chronic pharmacological
PARP inhibition and genetic deletion of PARP1 decreased
atherosclerosis, reduced enzymatic PARP activity, and
diminished expression of inducible nitric oxide synthase
(iNOS) and adhesion molecules. Furthermore, pharmacologi-
cal PARP inhibition reduced the number of plaque inﬂamma-
tory cells and diminished features of plaque vulnerability.
2. Methods
2.1 Animals
Experiments with the PARP inhibitor PJ34 were performed using
ApoE2/2 mice9 on a pure C57Bl/6J background. For the genetic
experiments, PARP12/24 mice (129SvEv background) were crossbred
with ApoE2/2 mice (C57Bl/6J background) in order to obtain
ApoE2/2PARP1þ/þ and ApoE2/2PARP12/2 mice that all had the
identical mixed 129SvEv/C57Bl/6J background.
2.2 Mouse experiments and poly(ADP-ribose)
polymerase inhibitor
Male ApoE2/2 mice9 or ApoE2/2PARP1þ/þ (n ¼ 9) and ApoE2/2
PARP12/2 (n ¼ 10) mice were fed a high-cholesterol diet (CD;
1.25% total cholesterol, D12108, Research Diets, New Brunswick,
NJ, USA) for 3 months starting at the age of 8 weeks. The pharma-
cological experiments were carried out as follows: After 4 weeks of
diet, PJ34 [N-(6-oxo-5,6-dihydro-phenanthridin-2-yl)-N,Ndimethyla-
cetamide, EMD Biosciences, San Diego, CA, USA], was administered
via subcutaneous implantation of a custom-made pellet (Innovative
Research of America, Sarasota, FL, USA); this pellet provided a con-
tinuous release of 250 mg PJ34/day for 60 days (n ¼ 25). We
selected this dosage based on previous studies that provided PJ34
parenterally up to 3 weeks.10 Mice with implantation of pellets con-
taining vehicle (placebo, n ¼ 25) as well as age-matched C57Bl/6J
wild-type mice (n ¼ 26) served as negative controls. At 20 weeks
of age, i.e. 8 weeks after pellet implantation, all animals were
euthanized with an overdose of isoﬂurane (Abbott; Baar, Switzer-
land) inhalation for tissue harvesting. For the genetic experiments,
wild-type mice with a 129SvEv/C57Bl/6J background were used as a
control group. All animal experiments were approved by the local
animal committee and performed in accordance with our insti-
tutional guidelines that conform to the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes
of Health (NIH Publication No. 85–23, revised 1996).
2.3 Blood chemistry and haematology
At the time of tissue harvesting, 0.5 to 1 ml of blood was drawn from
the right ventricle with heparinized syringes, immediately centri-
fuged at 48C, and the plasma stored at 2808C. Total cholesterol, tri-
glycerides, and free fatty acids were analysed using the reagents
TR13421, TR22421 (both Thermo Electron Clinical Chemistry & Auto-
mation Systems) and 994–75409 (Wako Chemicals GmbH, Neuss,
Germany), as recommended by the manufacturer. The lipid distri-
bution in plasma lipoprotein fractions was assessed by
fast-performance liquid chromatography gel ﬁltration with a Super-
ose 6 HR 10/30 column (Pharmacia, Uppsala, Sweden).11 Plasma
values of vascular cell adhesion molecule 1 (VCAM-1) (MVC00) and
intracellular adhesion molecule 1 (ICAM-1) (MIC100; both R&D
Systems, Inc., Minneapolis, MN, USA) were determined using
ELISA, and monocyte chemoattractant protein-1 (MCP-1), tumour
necrosis factor a (TNF-a), interferon g (IFN-g), and interleukin 6
(IL-6) using multiplex array systems (BD FACSArray Bioanalyzer
System and Becton Dickinson Cytometric Bead Array Mouse Inﬂam-
mation Kit 552364; BD Biosciences, Erembodegem, Belgium). For
haematologic analyses, blood drawn from the right ventricle was
transferred to vacutainer tubes (Becton Dickinson, Franklin Lakes,
NJ, USA) and analysed within 6 h.
2.4 Tissue harvesting and processing
After puncturing the left ventricle and cutting the right atrium,
vessels were rinsed brieﬂy with normal saline and the aorta was
excised after removing adventitial tissue and fat. For en face ana-
lyses, thoraco-abdominal aortae (from the left subclavian artery
to the iliac bifurcation) were opened longitudinally.12 For histologi-
cal examination, the aortic arch was embedded in OCT (optimal
cutting temperature) compound (Tissue-Tek; Sakura, The Nether-
lands), frozen on dry ice, and stored at –808C. For biochemical ana-
lyses, aortic arches were shock-frozen in liquid nitrogen and stored
at 2808C.
2.5 Western blotting
This technique was performed according to standard procedures
including stripping and re-probing of membranes as needed. The fol-
lowing primary antibodies were used: polyclonal rabbit antibodies
against PARP1 (ALX-210–619; Alexis Corporation, Lausen, Switzer-
land) and monoclonal mouse antibodies against poly-ADP-ribose
(ALX-210–890; Alexis) as well as iNOS (clone 6; BD Biosciences
Franklin Lakes, NJ, USA); primary monoclonal rat antibodies were
applied to detect CD106 (VCAM-1, clone MCA1229; Serotec,
Oxford, UK), CD62E (E-selectin, clone 10E9.6), CD62P (P-selectin,
clone RB40.34; both BD Biosciences Pharmingen), and a-tubulin
(clone B512; Sigma Chemical Co., St Louis, MO, USA). Secondary
peroxidase-labelled anti-species-speciﬁc IgG antibodies (Amersham
Biosciences, GE Healthcare Europe GmbH, Otelﬁngen, Switzerland)
were diluted 1 : 4000 and incubated with the membranes for 1 h at
room temperature (RT). Proteins were visualized after incubation of
the membranes in SuperSignal West Femto Maximum Sensitivity Sub-
strate for 5 min at RT. For PARP1 and a-tubulin, enhanced lumines-
cent substrate was used (Pierce Biotechnology, Inc., Lausanne,
Switzerland). Protein expression was quantiﬁed using Scion
ImageTM and expressed as ratio to tubulin or PARP1, respectively,
after normalizing to WT values.
2.6 En face plaque staining
For quantiﬁcation of atherosclerotic plaques, en face analysis of the
thoraco-abdominal aorta was performed as described.12 Plaque area
was visualized by fat staining (Oil-red O), photographed with a
digital camera (Olympus DP70, 12.5 megapixels) that was
mounted on an Olympus SZX951 microscope (Olympus Schweiz AG,
Schwerzenbach, Switzerland), and quantiﬁed (Analysis 5; SoftIma-
ging System, Munster, Germany).13
2.7 Histological examination
Plaque size and composition were analysed in at least four serial
longitudinal cryosections of the aortic arch (5 mm thickness,
50 mm intervals) that were thaw-mounted on glass slides (Super-
FrostPlus; Menzel GmbH und Co., Braunschweig, Germany). A
segment of the lesser curvature of the aortic arch was identiﬁed
by dropping a perpendicular axis from the beginning of the innomi-
nate artery to the lesser curvature and following a 3-mm distance
distal from this axis as described (see Supplementary material
online, Figure S1).14 Fat content was measured by ORO staining.
Collagen, ﬁbrous cap thickness, and necrotic core size were ana-
lysed by Elastica van Gieson (EVG) staining as described.15 All sec-
tions were photomicrographed with a digital camera (Olympus
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DP50-CU) mounted on an Olympus BX51 microscope, digitized and
analysed (Analysis 5, SoftImaging System).
2.8 Immunohistochemistry and
immunoﬂuorescence
Acetone-ﬁxed and rehydrated cryosections were incubated with
primary antibodies for 30 min at RT. The staining of CD106, CD62E,
and CD62P were performed with the same primary antibodies as
used for western blotting. Primary rat monoclonal antibodies were
used to stain the following antigens: CD68 (FA-11; Serotec), CD3
(KT3; Chemicon/Millipore, Billerica, MA, USA) and proliferation cell
nuclear antigen (PCNA) (PC10, Abcam, Cambridge, UK). iNOS was
detected with polyclonal rabbit antibodies (Serotec). Primary anti-
bodies were revealed by goat anti-species-speciﬁc immunoglobulin
antibodies, followed by alkaline phosphatase-labelled donkey anti-
bodies against goat immunoglobulins. Alkaline phosphatase was visu-
alized using naphthol AS-BI phosphate and new fuchsin as substrate.
Endogenous alkaline phosphatase was blocked by levamisole. Colour
reactions were performed at RT for 15 min with reagents from
Sigma. Sections were counterstained with haemalum and coverslips
mounted with glycerol and gelatine. Proliferation was determined
by indirect ﬂuorescent staining for PCNA using a mouse monoclonal
antibody (clone PC10; DakoCytomation, Glostrup, Denmark) followed
by an Alexa Fluor 488 conjugated anti-mouse antibody as secondary
reagent. Cell death was assessed via terminal deoxyribonucleotidyl
transferase-mediated dUTP nick-end labelling (TUNEL; Roche,
Rotkreuz, Switzerland).16 Nuclei were stained by 40-6-diamidino-2-
phenylindole (DAPI, Boehringer, Mannheim).
2.9 Statistics
Values are expressed as mean + SEM. An unpaired Student t-test or
ANOVA with post hoc Tukey’s test was used to compare results
between different groups. Signiﬁcance was accepted at the level
of P, 0.05.
3. Results
3.1 Plaque formation is reduced by chronic
poly(ADP-ribose) polymerase inhibition or
poly(ADP-ribose) polymerase 1 deletion
We examined the effects of chronic pharmacological inhi-
bition of PARP (by treatment with the PARP inhibitor PJ34)
and genetic PARP1 deletion on plaque formation in
atherosclerosis-prone apolipoprotein E knockout
(ApoE2/2) mice.9 After 12 weeks of a high-cholesterol
diet, the average en face plaque area in ApoE2/2 mice
treated with PJ34 for 8 weeks was reduced by 46% compared
with the plaque area in placebo-treated ApoE2/2 mice (n ¼
10, P ¼ 0.002, Figure 1A and B). Similarly, atherosclerosis in
PARP12/2ApoE2/2 mice decreased by 51% (n ¼ 10, P ¼
0.039) compared with PARP1þ/þApoE2/2 mice (n ¼ 9;
Figure 1C and D). ApoE2/2 mice treated with PJ34 appeared
healthy with the exception of 5 out of 25 mice those devel-
oped skin lesions; ApoE2/2 mice with or without PARP1 del-
etion were healthy with the exception of 1 out of 10
Figure 1 Aortic plaque formation is reduced by chronic poly(ADP-ribose) polymerase (PARP) inhibition or PARP1 deletion in apolipoprotein E knockout
(ApoE2/2) mice. (A) En face fat staining of thoraco-abdominal aortae from ApoE2/2 mice after 12 weeks of high-cholesterol diet; 8 weeks prior to harvesting,
mice received placebo or PJ34. (B) Plaque formation was signiﬁcantly decreased in PJ34-treated ApoE2/2 mice (n ¼ 10) compared with placebo-treated
ApoE2/2 mice (n ¼ 10, *P ¼ 0.002). (C) Fat staining of thoraco-abdominal aortae from PARP1þ/þApoE2/2 or PARP12/2ApoE2/2 mice after 12 weeks of high-
cholesterol diet. (D) Plaque formation was signiﬁcantly reduced in PARP12/2ApoE2/2 mice (n ¼ 10) compared with PARP1þ/þApoE2/2 mice (n ¼ 9, *P ¼
0.039); unpaired two-tailed Student t-test. Values are expressed as mean+ SEM.
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PARP12/2ApoE2/2 mice that developed a skin lesion (see
Supplementary material online, Figure S5).
3.2 Poly(ADP-ribose) polymerase 1 activity in
atherosclerotic aortae is diminished by chronic
poly(ADP-ribose) polymerase inhibition or
poly(ADP-ribose) polymerase 1 deletion
To ensure that effective PARP I inhibition or PARP1 deletion
was achieved in the target tissue, we analysed lysates of
aortic arches from a subset of the above mice for PARP1
expression and PARP activity. PARP1 expression did not
differ between wild-type mice and placebo- or PJ34-treated
ApoE2/2 mice (Figure 2A). However, PARP1 activity was
increased by a factor of three in aortae from placebo-
treated ApoE2/2 mice compared with wild-type mice (P ,
0.001), and markedly reduced in mice upon chronic treat-
ment with PJ34 (P , 0.05 vs. wild-type and P, 0.001 vs.
placebo) (Figure 2A and B). Similarly, aortic lysates from
PARP1þ/þApoE2/2 mice exhibited increased PARP activity
compared with lysates from wild-type mice. PARP activity
and PARP1 expression were not detectable in PARP12/2
ApoE2/2 mice. (Figure 2C and D).
3.3 Plasma lipid distribution upon chronic
poly(ADP-ribose) polymerase inhibition or
poly(ADP-ribose) polymerase 1 deletion
In order to investigate PARP-mediated effects on plasma
cholesterol, we measured levels of total cholesterol and
subfractions. ApoE2/2 mice on a high-cholesterol diet dis-
played markedly increased total cholesterol levels com-
pared with wild-type mice (see Supplementary material
online, Table S1and Figure S2A). However, there was no sig-
niﬁcant difference between PJ34- and placebo-treated
ApoE2/2 mice. Interestingly, total cholesterol levels were
increased in PARP12/2ApoE2/2 compared with PARP1þ/þ
ApoE2/2 mice. This increase affected particularly the
intermediate-density lipoprotein (IDL) and low-density lipo-
protein (LDL) subfractions (see Supplementary material
online, Table S2 and Figure S3A).
3.4 Expression of adhesion molecules in
atherosclerotic aortae is decreased by chronic
poly(ADP-ribose) polymerase inhibition or
poly(ADP-ribose) polymerase 1 deletion
To investigate the putative mechanisms mediating reduced
plaque formation in PJ34-treated or PARP1-deﬁcient athero-
sclerotic mice, we analysed protein expression of adhesion
molecules in aortic arch lysates from the same groups of
animals. E-selectin, P-selectin, VCAM-1, and iNOS were
barely detectable in wild-type mice without atherosclerosis,
but their expression was signiﬁcantly induced in placebo-
treated ApoE2/2 mice with abundant atherosclerotic
plaques (Figure 3A and B). Chronic treatment with PJ34
markedly decreased E-selectin, P-selectin, VCAM-1, and
iNOS protein levels (Figure 3A and B). Complementary
immunohistochemical stainings of aortic arches conﬁrmed
these ﬁndings (see Supplementary material online, Figure
Figure 2 Poly(ADP-ribose) polymerase (PARP) activity in atherosclerotic aortae is diminished by chronic PARP inhibition or PARP1 deletion. (A and B) Western
blots and graph showing PAR [poly(ADP)-ribose; a measure of PARP activity] and PARP1 protein in aortic arch lysates obtained from wild-type (WT), placebo-, or
PJ34-treated ApoE2/2 mice; a-tubulin served as internal control for protein loading. PARP activity is given as a ratio to PARP1 protein and normalized to WT
values. n ¼ 4 in each group. *P , 0.001; #P , 0.05. (C and D) Western blots and graph showing PAR and PARP1 protein in aortic arch lysates obtained from
WT, PARP1þ/þApoE2/2, or PARP12/2ApoE2/2 mice; a-tubulin served as internal control for protein loading. PARP activity is given as a ratio to PARP1
protein and normalized to WT values. n ¼ 4 in each group. *P , 0.001; n/d, not detectable. One-way ANOVA with post hoc Tukey’s test. Values are expressed
as mean+ SEM.
PARP1 is required in atherosclerosis 161
S4). In parallel, increased expression of E-selectin, P-
selectin, VCAM-1, and iNOS was observed in aortic arch
lysates from PARP1þ/þApoE2/2 mice, whereas these pro-
teins were not detectable in PARP12/2ApoE2/2 mice
(Figure 3C and D).
3.5 Number of inﬂammatory cells and features of
plaque vulnerability are reduced by chronic
poly(ADP-ribose) polymerase inhibition
Inﬂammation is not only crucial in the early stages of ather-
ogenesis related to plaque initiation, but also contributes to
progression of late atherosclerotic events implicated in
advanced lesions and plaque vulnerability.17 Therefore, we
quantiﬁed plaque inﬂammation in longitudinal sections of
aortic arches of placebo- (n ¼ 9) or PJ34-treated (n ¼ 6)
ApoE2/2 mice (see Supplementary material online, Figure
S1). Compared with placebo administration, chronic PJ34
treatment signiﬁcantly decreased plaque areas (Oil-red
O-stained areas, P ¼ 0.021; Figure 4A), plaque macrophages
(CD68-positive areas, P ¼ 0.018; Figure 4B, and T-cells
(CD3-positive areas, P ¼ 0.043; Figure 4C).
To address whether PARP affects plaque stability, we
assessed parameters of plaque vulnerability in serial
Figure 3 Expression of adhesion molecules in atherosclerotic aortae is decreased by chronic poly(ADP-ribose) polymerase (PARP) inhibition or PARP1 deletion.
(A) Western blots of E-selectin, P-selectin, vascular cell adhesion molecule 1 (VCAM-1), and nitric oxide synthase (iNOS) in aortic arch lysates obtained from
wild-type (WT), placebo-, or PJ34-treated apolipoprotein E knockout (ApoE2/2) mice; n ¼ 4 in each group. (B) Quantiﬁcation of protein expression is given
as ratio to a-tubulin (loading control) and normalized to WT. (C) Western blots of E-selectin, P-selectin, VCAM-1, and iNOS in aortic arch lysates obtained
from WT, PARP1þ/þApoE2/2, or PARP12/2ApoE2/2 mice. (D) Quantiﬁcation of protein expression is given as ratio to a-tubulin (loading control) and normalized
to WT; n ¼ 4 in each group. *P , 0.001; #P , 0.01; n/d, not detectable. One-way ANOVA with post hoc Tukey’s test. Values are expressed as mean+ SEM.
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longitudinal sections of aortic arches in placebo- or
PJ34-treated ApoE2/2 mice. Compared with placebo
administration, chronic PJ34 treatment increased ﬁbrous
cap thickness (P ¼ 0.023) and reduced the necrotic core
diameter (P ¼ 0.028; Figure 5A). Furthermore, there was a
trend to increased collagen content of atherosclerotic
plaques in PJ34-treated compared with placebo-treated
ApoE2/2 mice (P ¼ 0.051; Figure 5A). Cell death was
lower in PJ34-treated ApoE2/2 mice (P ¼ 0.027; Figure
5B), whereas proliferation remained unchanged (data not
shown).
3.6 Systemic mediators of inﬂammation are not
affected by chronic poly(ADP-ribose) polymerase
inhibition
To compare above local with systemic parameters of inﬂam-
mation, we determined levels of plasma inﬂammatory cyto-
kines and blood haematology counts. Plasma analyses of the
inﬂammatory markers MCP-1, IFN-g, IL-6, VCAM-1, ICAM-1,
and TNF-a showed no signiﬁcant differences between
placebo- and PJ34-treated ApoE2/2 mice, or between
PARP1þ/þApoE2/2 and PARP12/2ApoE2/2 mice. Overall
blood leukocyte counts as well as blood monocytes, lympho-
cytes, and neutrophils were unchanged (see Supplementary
material online, Tables S3 and S4).
4. Discussion
Our results provide both pharmacological and genetic evi-
dence that PARP1 increases expression of adhesion mol-
ecules, promotes plaque inﬂammation, and induces
features of plaque vulnerability.
Speciﬁcally, we show that pharmacological inhibition of
PARP via chronic PJ34 administration as well as genetic
deﬁciency of PARP1 markedly decreased plaque formation
in atherosclerosis, a chronic inﬂammatory disease. Our ﬁnd-
ings match previous reports that demonstrate the import-
ance of PARP1 for acute inﬂammatory diseases.5,7,8,18,19 A
most recent report shows beneﬁcial effects of pharmaco-
logical PARP inhibition and PARP1 deletion on the develop-
ment of atherosclerotic plaques in mice.20 The authors
describe an inhibition of MCP-1 expression in atherosclerotic
murine aortae, via an NFkB-dependent pathway. Beyond this
study, we identiﬁed adhesion molecules as critical mediators
of PARP inhibition or PARP1 deletion, leading to a reduction
in inﬂammatory activity within the atherosclerotic plaque.
Our results demonstrate that PARP activity was enhanced
in aortae of atherosclerotic mice compared with non-
diseased arteries of wild-type mice. Overall PARP activity
in atherosclerotic aortae was markedly decreased upon
chronic unspeciﬁc PARP inhibition with PJ34 and was not
detectable in PARP12/2ApoE2/2 mice. Our observations
further show a speciﬁc increase in PARP1 activity in athero-
genesis. They suggest a subordinate role for other PARP iso-
forms in this process given the lack of PARP activity
(generated by PARP isoforms other than PARP1) in PARP12/2
ApoE2/2 mice. Thus, PARP1 is likely to be responsible for
most of the effects attributed to the PARP family in athero-
genesis. PARP is known to be activated via DNA damage
mediated by free radicals and reactive oxygen species.
Reactive oxygen species are widely present in inﬂammatory
conditions such as atherosclerosis, and are therefore likely
to be one of the key triggers of PARP activation in athero-
sclerotic lesions.
Interestingly, PARP1 expression remained similar in non-
diseased arteries from wild-type mice and in aortae from
atherosclerotic mice treated with the PARP inhibitor or
placebo. As expected, PARP1 expression was undetectable
in PARP12/2ApoE2/2 mice. Enhanced PARP1 expression
Figure 4 Number of inﬂammatory cells is reduced by chronic poly(ADP-ribose) polymerase (PARP) inhibition. Longitudinal aortic arch sections of placebo- (n ¼
9) or PJ34-treated (n ¼ 6) apolipoprotein E knockout (ApoE2/2) mice (left panels) stained with (A) oil-red O (ORO), (B) antibodies against CD68, or (C) antibodies
against CD3 (arrows pointing to positive stainings), with the corresponding quantiﬁcations (right panels). *P , 0.05; unparied two-tailed Student t-test. Values
are expressed as mean+ SEM.
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has been described in human atherosclerotic specimens,21
but this discrepancy may be explained by species
differences.
High levels of plasma triglycerides or cholesterol, in par-
ticular LDL cholesterol, are established clinical risk factors
and key modulators of atherosclerosis.22 Interestingly,
total cholesterol levels were increased in PARP12/2
ApoE2/2 compared with PARP1þ/þApoE2/2 mice. We con-
sider this effect not relevant for atherogenesis as PARP12/2
ApoE2/2 mice exhibited less atherosclerosis. Furthermore,
pharmacological inhibition of PARP activity did not affect
the lipid proﬁle. It is known that a therapeutic agent may
reduce atherogenesis independent of serum lipid levels.
For example, Steffens et al.23 have found a reduction in
the progression of atherosclerosis in ApoE2/2 mice treated
with low dose of the phytochemical tetrahydrocannabinol.
As in our study, this decrease in atherosclerosis was indepen-
dent of serum cholesterol and triglyceride levels.
PARP inhibition decreases the expression of
pro-inﬂammatory genes such as inducible iNOS and VCAM-1
in acute inﬂammatory conditions.10 Therefore, we studied
inﬂammatory mediators such iNOS, VCAM-1, P-, and E-
selectin in atherosclerotic ApoE2/2 mice to delineate poss-
ible mechanisms of PARP-dependent atherogenesis. The
expression of these mediators was markedly decreased by
chronic pharmacological PARP inhibition and virtually abol-
ished in the presence of PARP1 deﬁciency. Our results
suggest that inhibition of PARP or deletion of PARP1 reduce
plaque initiation and progression in atherosclerosis-prone
mice by decreasing expression of adhesion molecules and
iNOS. This setting would inhibit the recruitment of
monocyte-derived macrophages and T-cells to atherosclero-
tic plaques. The importance of P-selectin,24 E-selectin,25
VCAM-1,26 and iNOS27 in atherogenesis is well documented.
We propose that activation of these adhesion molecules
may depend, at least in part, on PARP as a co-activator in
Figure 5 Features of plaque vulnerability are diminished by chronic poly(ADP-ribose) polymerase (PARP) inhibition. Aortic arch sections of placebo- (n ¼ 12) or
PJ34-treated (n ¼ 12) ApoE2/2 mice stained with (A) Elastica van Gieson (EVG); quantiﬁcations of ﬁbrous cap thickness (arrows), necrotic core diameter, *P ,
0.05 (dashed line, bottom), and collagen content (P ¼ 0.051). Aortic arch sections of placebo- or PJ34-treated ApoE2/2 mice stained with (B) TUNEL, P ¼ 0.027
[arrows indicating TUNEL-positive nuclei and their complementary 40-6-diamidino-2-phenylindole (DAPI) stainings in the same sections] and the corresponding
quantiﬁcations; unparied two-tailed Student t-test. Bars ¼ 50 mm. Values are expressed as mean+ SEM.
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NF-kB-mediated transcription.28,29 Because NF-kB is induced
in atherosclerosis,1 our ﬁndings suggest that PARP1 may
increase induction of adhesion molecules in atherosclerotic
plaques via NF-kB.
In accordance with the decreased expression of adhesion
molecules by either chronic PARP inhibition or PARP1 del-
etion, we found a marked reduction of macrophages and
T-cells in atherosclerotic plaques. These ﬁndings suggest
that chronic pharmacological PARP inhibition reduces
inﬂammatory cell recruitment resulting in fewer inﬂamma-
tory cells in the subintimal space of aortae in ApoE2/2
mice. In agreement, PARP inhibition has been shown to
decrease the inﬁltration of neutrophils in response to
acute zymosan-induced inﬂammation in mice and rats.30
Our blood counts and plasma cytokines imply that the
changes in adhesion molecules and inﬂammatory cells in
atherosclerotic aortae did not affect systemic parameters
of inﬂammation. We speculate that the critical changes in
PARP activity occur in endothelial cells and monocytes/
macrophages, thereby leading to the decrease in adhesion
molecules and iNOS in atherosclerotic lesions. The reduction
of PARP activity may also affect progression of atherosclero-
sis via secondary mechanisms, independent of adhesion mol-
ecule expression.
The reduced inﬂammation in response to chronic PARP
inhibition is likely to explain the increased ﬁbrous cap thick-
ness and smaller necrotic core that are both features of
increased plaque stability. In accordance with these ﬁnd-
ings, genetic deletion of the immune mediator CD156 or
its inhibition by anti-CD40 antibody decreases atherosclero-
sis progression and augments atherosclerotic plaque stab-
ility by decreasing plaque leukocyte content.14,15 In
addition, we found reduced TUNEL-positive cells in
advanced plaques of atherosclerotic mice treated with the
PARP inhibitor. These ﬁndings suggest that increased PARP1
activity facilitates cell death in murine atherosclerotic
lesions. In fact, in a stroke model, PARP1-deﬁcient mice
exhibit a marked reduction in cortical necrosis.31 Comp-
lementary to our ﬁndings, increased smooth muscle cell
death in murine atherosclerotic plaques induces features
of plaque vulnerability.32 These ﬁndings imply that chronic
PARP inhibition enhances features of plaque stability.
While most groups applying PJ34 or other PARP inhibitors
have given the drug parenterally, oral application of PJ34
has also been demonstrated to protect against the deleter-
ious effects of various inﬂammatory diseases.8,10 Therefore,
we conclude that PJ34 or related compounds are absorbable
if given orally and we extrapolate that they should be effec-
tive when given to humans. However, from a clinical point of
view, a speciﬁc PARP1 inhibitor – as opposed to an unspeciﬁc
PARP inhibitor – seems more desirable for the following
reasons: in our study, PARP1 deletion was sufﬁcient to
decrease aortic PARP activity and reduce atherogenesis in
mice by about 50%. Thus, speciﬁc PARP1 inhibition should
be sufﬁcient to reproduce these effects in patients. In
addition, speciﬁc inhibition is likely to induce less side
effects.
In our study, we found that chronic PARP inhibition induces
skin lesions in about a ﬁfth of PJ34-treated ApoE2/2 mice
and in about a tenth of ApoE2/2PARP12/2 mice. Similarly,
the development of skin lesions has previously been
reported to occur in a third of older PARP1-deﬁcient
mice.4 These ﬁndings suggest a possible link between skin
lesions and PARP inhibition or PARP1 deﬁciency. No such
side effects, however, have been reported with newer gen-
erations of PARP inhibitors used in clinical studies.33,34
We conclude that endogenous PARP1 enhances atherogen-
esis by increasing adhesion molecule expression with endo-
thelial activation, enhancing plaque inﬂammation with
macrophages and T-cells, and by inducing features of
plaque vulnerability. Thus, inhibition of enzymatic PARP1
activity may represent a promising therapeutic target in
atherosclerosis.
Supplementary material
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